Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558410 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,118
- Enrollment target
NCT05558410 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 1,118 participants.
The verdict
NCT05558410, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,118 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Interventions
- DRUG Placebo (matched to SUZ)
- DRUG HB/APAP
- DRUG Placebo (matched to HB/APAP)
- DRUG Suzetrigine (SUZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,118 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2023-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05558410
The ClinicalTrials.gov registry entry for NCT05558410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (matched to SUZ) is the first listed.
NCT05558410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05558410 about?
NCT05558410 is a clinical study titled "Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty". The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
What is the current status of trial NCT05558410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,118 participants. The study started on 2022-10-10. Estimated completion is 2023-09-11.
What interventions are being tested in trial NCT05558410?
The interventions under investigation include: Placebo (matched to SUZ) (DRUG), HB/APAP (DRUG), Placebo (matched to HB/APAP) (DRUG), Suzetrigine (SUZ) (DRUG).
Who is sponsoring clinical trial NCT05558410?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.